Swedish deals surge


In June Stockholm-based Athera Biotechnologies struck a deal with German pharma Boehringer Ingelheim to co-develop antibodies to treat cardiovascular disease. Boehringer paid an unspecified amount to acquire Athera’s antibody program after a phase 1 study is complete. Athera will use the option money plus a recent EU grant to fund early-stage work on its… (More)
DOI: 10.1038/nbt0913-772


Cite this paper

@article{Sinha2013SwedishDS, title={Swedish deals surge}, author={Gunjan Sinha}, journal={Nature Biotechnology}, year={2013}, volume={31}, pages={772-772} }